ICCM

Business Context and Reporting Period

Company: IceCure Medical Ltd. (ICCM)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: IceCure is a commercial-stage medical device company developing cryoablation systems (freezing technology) for treating tumors. Its lead product is the ProSense system. The company is currently focused on obtaining FDA De Novo classification for the treatment of early-stage breast cancer, a decision expected after Q1 2025 following a favorable FDA Advisory Panel vote in November 2024.

Key Financial Metrics (Year Ended Dec 31, 2024)

Note: The filing text does not provide a specific debt figure other than lease liabilities ($459k total). The company has no long-term debt.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased slightly by 2% ($62k) to $3.29 million. This was driven by a 22% increase in disposable sales ($1.83M), offset by a 6% decrease in system sales and a 64% drop in revenue from exclusive distribution agreements (Japan).
• Geographic Shifts: Revenue from India surged 279% to $413k, and the U.S. grew 16% to $870k. Conversely, China revenue collapsed 91% to $41k due to distributor performance issues.
• Expense Trends: Sales and marketing expenses rose 42% to $6.3M, primarily due to costs associated with the FDA De Novo classification process and Advisory Panel. R&D expenses decreased 14% to $7.1M due to reduced development costs for the XSense system.
• Liquidity: Cash and cash equivalents decreased by approximately $3M year-over-year. Net cash used in operating activities was $12.6M, partially offset by $9.2M in net proceeds from an At-The-Market (ATM) equity offering.

Guidance, Outlook, and Risks

Going Concern Warning

Management and the independent auditor have raised substantial doubt about the Company's ability to continue as a going concern. As of March 24, 2025, cash balances were approximately $6.0 million, which is insufficient to fund planned operations for the next 12 months. The company expects to continue incurring significant losses and will require substantial additional funding.

Regulatory Outlook

The critical near-term catalyst is the FDA's decision on the De Novo classification for ProSense for breast cancer, expected after Q1 2025. An FDA Advisory Panel voted favorably in November 2024. Success is required to secure reimbursement codes (CPT Category I) and drive significant revenue growth.

Key Risks

• Capital Requirements: Failure to raise additional capital could force the company to curtail R&D or commercialization.
• Geopolitical Instability: Operations are based in Israel. Ongoing multi-front conflicts (Hamas, Hezbollah, Iran) pose risks to operations, supply chains, and employee availability (9 employees called to reserve duty as of March 2025).
• Distributor Performance: The China distributor (Shanghai Medtronic Zhikang) is unlikely to meet minimum purchase targets, and the Japan distributor (Terumo) has not yet secured regulatory approval.

Investor Verification Checklist

• Cash Runway: Verify the current cash balance and burn rate to assess the immediate need for capital raises.
• FDA Decision Timeline: Monitor the official FDA decision on the ProSense breast cancer De Novo request (expected post-Q1 2025).
• China Distribution: Confirm the status of the relationship with Shanghai Medtronic Zhikang and the transition to direct sales via Beijing Turing.
• Israel Conflict Impact: Assess the operational impact of the ongoing war, including supply chain disruptions and employee reserve duty.
• Equity Dilution: Review the terms of the new ATM facility (up to $13.96M) and recent share issuances to understand dilution risks.